In vitro characterization of immune-related properties of human fetal bone cells for potential tissue engineering applications by Montjovent, Marc-Olivier et al.
In Vitro Characterization of Immune-Related Properties
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We describe herein some immunological properties of human fetal bone cells recently tested for bone tissue-
engineering applications. Adult mesenchymal stem cells (MSCs) and osteoblasts were included in the study for
comparison. Surface markers involved in bone metabolism and immune recognition were analyzed using flow
cytometry before and after differentiation or treatment with cytokines. Immunomodulatory properties were
studied on activated peripheral blood mononuclear cells (PBMCs). The immuno-profile of fetal bone cells was
further investigated at the gene expression level. Fetal bone cells and adult MSCs were positive for Stro-1,
alkaline phosphatase, CD10, CD44, CD54, and b2-microglobulin, but human leukocyte antigen (HLA)-I and
CD80 were less present than on adult osteoblasts. All cells were negative for HLA-II. Treatment with recom-
binant human interferon gamma increased the presence of HLA-I in adult cells much more than in fetal cells. In
the presence of activated PBMCs, fetal cells had antiproliferative effects, although with patterns not always
comparable with those of adult MSCs and osteoblasts. Because of the immunological profile, and with their
more-differentiated phenotype than of stem cells, fetal bone cells present an interesting potential for allogeneic
cell source in tissue-engineering applications.
Introduction
In the area of orthopedic medicine, cell-based ap-proaches include bone marrow preparations,1 mesenchy-
mal stem cells (MSCs),2,3 a hybrid approach of stem cells
with gene therapy,4 and osteoprogenitor cells.5
The use of bone marrow–derived MSCs (BM-MSCs) seems
also to represent a promising approach. Local delivery of
purified MSCs was used for spine fusion,6 segmental bone
defects,2 and craniotomy defects.3 Similar approaches have
also been described for the repair of defects in articular
cartilage7,8 and tendon.9 However, there are several limita-
tions associated with the use of BM-MSCs for bone regen-
eration. First, the scarcity of osteoprogenitors in mature bone
marrow, especially from elderly individuals, has been de-
scribed clinically.10–13 Furthermore, an age dependency was
detected such that the use of bone marrow cells from aged
rats seeded on porous hydroxyapatite scaffolds implanted
subcutaneously was associated with less ectopic bone for-
mation than from younger donors.14 Additionally, although
adult MSCs may differentiate into several lineages depend-
ing on the local extracellular signal, they are not committed
to differentiation into the osteoblast lineage.
BM-MSCs have been considered to have unique immu-
nologically privileged properties,15 but application occurred
in heavily immunosuppressed recipients, and recent data
in immunocompetent animals challenged their immuno-
privilege.16 Donor-derived MSCs were immunogenic in an
allogeneic host and stimulated donor graft rejection in a non-
myeloablative setting. However, BM-MSC immunomodula-
tory effects were verified by inhibiting T-cell allogeneic
proliferation induced in mixed lymphocyte cultures or
by non-specific mitogens. In general, fetal MSCs were shown
to express lower levels of human leukocyte antigen (HLA)
class I molecules than adult MSCs,17 indicating an im-
munoprivilege of fetal cells.
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Stem cell populations with osteogenic potential have been
identified in other mesenchymal tissues than bone marrow;
skeletal muscle18,19 and fat20 may serve as alternative sources
of precursor cells for bone regeneration. Alternatively to the
reimplantation of MSCs, an osteoprogenitor cell line (OPC-1)
has been established21 and used in combination with a porous
carrier and recombinant human bone morphogenic protein-
2, showing synergistic effects on osteoinduction in vivo.5
The use of human fetal bone cells for tissue engineering
has recently been described. Fetal bone cells were shown to
proliferate, differentiate, and finally to mineralize their ex-
tracellular matrix in vitro.22 Furthermore, they promoted new
bone formation in vivo in immunocompetent rats.23 Because
fetal bone cells have already engaged into the osteoblast
lineage, they are easier to isolate than fetal MSCs, and a cell
bank may be generated from only a few donors, overcoming
the cell-sourcing problems associated with the use of
MSCs. Fetal cells may be considered as a potential alternative
to MSCs.
The aim of this study was to compare the immunogenicity
of fetal bone cells in vitro with that of BM-MSCs and differ-
entiated adult osteoblasts from the perspective of using them
as an allogeneic cell source for bone tissue engineering. The
expression of cell surface markers involved in immune rec-
ognition (HLA-I, HLA-II, CD80, CD86), bone metabolism
(alkaline phosphatase (ALP), Stro-1, CD10, CD44), or both
(CD54, b2-microglobulin) was determined. Furthermore, the
ability of fetal cells to regulate proliferation of activated pe-
ripheral blood mononuclear cells (PBMCs) was evaluated.
Materials and Methods
Cell sources
Human trabecular bone biopsies at femoral locations ob-
tained from five adult men (median age 57.4; range 40–79)
after orthopedic surgery and from five fetuses (median ges-
tational age 14.8 weeks; range 13–16) after voluntary inter-
ruption of pregnancy were used. Biopsies were obtained in
accordance with the Ethics Committee of University Hospital
at Lausanne (Ethical Protocol 51=01). Bone samples were
mechanically dissociated with a scalpel blade and trans-
ferred to 10-cm culture-grade plates, where cell outgrowth
was seen within 1 to 5 days for fetal and 10 to 12 days for
adult tissue under normal culture conditions (Dulbecco’s
modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA),
10% fetal calf serum (FCS; Sigma-Aldrich, St Louis, MO),
4mM L-glutamine (Invitrogen)). Adult BM-MSCs were iso-
lated at the University Hospital Basel (Ethical Protocol rev
78=07) from the posterior iliac crest of the pelvic bone from
five healthy volunteers (median age 44.7; range 34–52) as
described previously.24 No age or sex exclusion criteria were
fixed.
Cell culture
Bone cells were maintained in culture by passaging once a
week and culturing at 378C in a humidified, 5% carbon dioxide
atmosphere in DMEM, 10% FCS, and 4mM L-glutamine.
Culture medium was changed twice a week. When close
to confluence, the cells were detached using trypsin-
ethylenediaminetetraacetic acid (EDTA; Invitrogen) and see-
ded at a density of 6,000 cells=cm2 in T80 flasks. For the
characterization of bone cells using a fluorescence-activated
cell sorter (FACS), cytokines and osteogenic factors were tes-
ted as follows: 100U=mL of recombinant human interferon
gamma (rhIFN-g; exposition of 7 days, Sigma-Aldrich);
500U=mL of recombinant human tumor necrosis factor alpha
(rhTNF-a) (exposition of 7 days, Sigma-Aldrich); 100U=mL of
rhIFN-g and 500U=mL of rhTNF-a (exposition of 7 days);
50mg=mL of ascorbic acid, 1mM of b-glycerophosphate,
10 nM of dexamethasone (differentiation mix, exposition of 14
days); differentiation mix and 100U=mL of rhIFN-g (exposi-
tion of 14 days to the differentiationmix, togetherwith rhIFN-g
during the 7 last days); differentiation mix and 500U=mL of
rhTNF-a (exposition of 14 days to the differentiation mix, to-
gether with rhTNF-a during the last 7 days).
The effect of treatment with 100U=mL of rhIFN-g,
500U=mL of rhTNF-a, or differentiation mix described above
were further studied on fetal bone cells at the gene expres-
sion level using real-time polymerase chain reaction (PCR).
Cells from passages 3 to 6 were used for all experimen-
tations.
BM-MSC culture conditions
Cells were cultured in low-glucose DMEM or alpha-
modified minimum essential medium (Invitrogen) supple-
mented with 10% fetal bovine serum, as already described,
without any additional growth factors.25 BM-MSCs were
passaged up to a maximum of four times and were not
stored frozen longer than 3 to 4 months before use in culture.
Flow cytometric cell characterization
Cells were seeded at a density of 6,000 cells=cm2 in T80
flasks, and treatments were started 24 h later, with culture
medium changed every second day. Osteoblastic cells were
detached using a solution of 40% EDTA, washed, and fixed
for 30min in ice-cold 4% formaldehyde. After fixation, cells
were washed and suspended at 1x106 cells=mL in PBS with
3% FCS.
Aliquots of 100mL of the cell suspensions were incubated
for 60min in the dark at 48C with the appropriate monoclo-
nal antibody. For this study, we used phycoerythrin (PE)-
conjugated antibodies against CD10; HLA-A, -B, and -C
(Becton Dickinson Biosciences, Franklin Lakes, NJ); CD14;
CD86 (R&D Systems, Minneapolis, MN); and fluorescein
isothiocyanate (FITC)- conjugated antibodies against CD54,
CD80 (R&D Systems), HLA-DR, -DP, and -DQ, and b2-
microglobulin (Becton Dickinson Biosciences). Primary spe-
cific antibodies against CD34 (Zymed Laboratories Inc., South
San Francisco, CA), CD44, CD45, and ALP (R&D Systems)
were detected using PE-conjugated goat anti-mouse immu-
noglobulin (Ig)G (1, 2a, 2b, 3) ( Jackson ImmunoResearch,
West Grove, PA), whereas Stro-1 (R&D Systems)was detected
using FITC-conjugated goat anti-mouse IgM ( Jackson Im-
munoResearch). Nonspecific fluorescence was determined
using equal aliquots of cells. Each fluorescence analysis in-
cluded appropriate PE- and FITC-conjugated negative iso-
type controls. A FACSCalibur flow cytometer (Becton
Dickinson Biosciences) was used for analysis of fluorescent
cells based on a reading of 5,000 gated cells per sample.
Percentage of positive cells was calculated upon sub-
straction of the respective control. Up to 5% of positive cells,
cells were not considered to express the investigated protein.
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In all experiments, a constant setting of the FACS was
maintained (gain, amplifier, and photomultiplier voltage).
RNA isolation and purification
RNA isolation and purification procedures were per-
formed using Nucleospin RNA II columns (Macherey-Nagel,
Du¨ren, Germany). RNA was eluted in 60 mL of RNase-free
water and stored at !808C until experimentation.
First-strand synthesis
For each sample, 1 mg of total RNA was reverse-tran-
scribed using the Taqman Universal PCR reagents with
random hexamers (Applied Biosystems, Foster City, CA).
Reaction volumes were fixed at 50 mL. The ABI Prism 7700
(Applied Biosystems) was programmed as following: 258C
10min, 488C 30min, 958C 5min.
Gene expression
The samples were assessed for gene expression using the
TaqMan Low-Density Arrays Immune Panel (Applied Bio-
systems). The list of targets and endogenous controls can be
downloaded from https:==products.appliedbiosystems.com.
The equivalent of 2.2 ng of total RNA was loaded into each of
the 384 wells. Amplifications were monitored using the ABI
Prism 7900 (Applied-Biosystems). Thermal cycle conditions
were: 508C 2min and 958C 10min and then 50 cycles at 958C
15 sec and 608C 1min. Because of statistical fluctuations ob-
served with rare copies of messenger RNAs, the cycle
number at the threshold level of log-based fluorescence (CT)
was arbitrarily fixed to 30 to distinguish genes that are
constitutively expressed from genes which are not expressed.
Measurements were performed in quadruplicate for each
gene of interest and for the five different fetal donors.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)prim-
ers and probes were used as internal controls. Data were
analyzed using SDS Software v2.2 (Applied Biosystems).
Relative gene expressions were analyzed with the 2-DDCT
method.26 Normalized to GAPDH, each gene expression was
compared with the %CT calibrator value from the untreated
group. For each gene, results were expressed as the relative
quantity (RQ) with the range determined by evaluating the
expression: 2-DDCT, with DDCTþ s and DDCT! s, where s is
the standard deviation of the DDCT value. Gene expression
inductions due to cytokines were classified as follows:þ for
1<RQ# 10;þþ for 10<RQ# 100; andþþþ for RQ> 100.
The mean RQ values of five donors were included.
In vitro immunomodulatory properties of bone cells
and adult BM-MSCs on actively proliferating PBMCs
The proliferation of PBMCs from healthy donors in the
presence of bone cells was performed in 96-well plates fol-
lowing a method described elsewhere.25 Bone cells were ir-
radiated to ensure that incorporation of hydrogen (3H)
occurred only in PBMCs. Previous results indicated that ac-
tive cell proliferation is not required to induce the reported
antiproliferative effect, nor is irradiation responsible for such
antiproliferative effect. Briefly, bone cells were irradiated
(30Gy); seeded at dilutions of 0.4, 2, 10, or 50#103 cells per
well; and allowed to attach for at least 1 h at 378C before
PBMCs isolated from healthy donors using density gradient
centrifugation (Lymphoprep, Axis-Shield PoC AS, Oslo,
Norway) were added. PBMCs (105 cells per well) in RPMI
1640 medium supplemented with 5% pooled human serum
were added with or without the combination of anti-CD3e
monoclonal antibody (anti-CD3e mAb, 0.5 mg=mL, gift
from Antonio Lanzavecchia, Bellinzona, Switzerland) and
anti-CD28 monoclonal antibody (anti-CD28mAb, 1mg=mL,
Becton Dickinson Biosciences). The plates were incubated
at 378C for 48 h, then pulsed for 18 h with 1mCi=well 3H-
thymidine (GE Healthcare, Little Chalfont, United Kingdom)
and harvested and the 3H cpm counted. Each condition was
tested in triplicate.
Statistical analyses
For each cell type, five different donors were tested in
triplicate. For the FACS analysis, a representative value from
each donor was used to calculate mean values and standard
deviations (SDs) for fetal cells, adult MSCs and osteoblasts.
The Student t-test was applied to assess whether the means
of two groups were statistically different from each other.
A value of p< 0.05 was taken as a significant difference
(otherwise noted NS).
Results
Flow cytometric characterization of bone cells
The characterization of bone cells for the presence of se-
lected surface markers is summarized in Table 1. Fetal bone
cells exhibited a strong expression of Stro-1 (91.6$ 8.1%) and
ALP (82.4$ 7.4%). These cells were also positive for CD10,
CD44, CD54, and the HLA-I-associated b2-microglobulin.
Additionally, lower expressions of HLA-I and CD80 were
observed than with adult osteoblast cells (–88%, p< 0.05 and
–100% p< 0.001, respectively).
Adult MSCs showed an intermediate pattern; they were
also positive for Stro-1 (90.2$ 4.3%) and ALP (71.6$ 19.3%),
but HLA-I and CD80 were less present than on adult oste-
oblasts (–27% ns, and –75%, p< 0.05, respectively). All cells
were negative for HLA-II. Moreover, the absence of CD14,
CD34, and CD45 antigens, verified for all donors, showed
that there was no contaminating hematopoietic stem cells at
the passages considered.
Effects of rhIFN-g and rhTNF-a cytokines alone
or in combination on HLA-I, HLA-II, and CD54
cell-surface proteins
The effects of rhIFN-g and rhTNF-a cytokines on selected
surface markers of bone cells are summarized in Table 2. After
treatment with rhIFN-g, the number of fetal bone cells
expressing HLA-II (91-fold, p< 0.001) and CD54 increased
(0.1-fold, p< 0.01), with a dramatic augmentation of mean
fluorescence intensities (data not shown), whereas the mean
fluorescence intensity of HLA-I was only slightly affected
(data not shown). Treatment with rhTNF-a had only an in-
fluence on the percentage of HLA-I- (3.1-fold, p< 0.001) and
CD54-positive cells (0.1-foldp< 0.01),withnoeffectonHLA-II.
Concomitant treatment with rhIFN-g and rhTNF-a led to a
synergistic effect on CD54 in terms of mean fluorescence in-
tensity (data not shown). These observations were also veri-
fied with adult MSCs and adult osteoblasts. rhIFN-g increased
the presence of HLA-I positive adult cells tested (1.6-fold,
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p< 0.001 for BM-MSCs and 0.8-fold, p¼ 0.001 for adult oste-
oblasts). The changes observed in terms of mean fluorescence
intensities were higher with adult cells than with fetal cells
(data not shown). Treatment of differentiation had no influ-
ence on HLA-I, HLA-II, and CD54 and did not change the
effect of rhIFN-g or rhTNF-a on these surface markers for the
different bone cells considered here (data not shown).
Gene expression
The immune profile of fetal bone cells was investigated
using quantitative real-time PCR. The results of the genes
that are discussed hereafter are shown in Table 3. The ex-
pression profile of all analyzed genes is presented in sup-
plementary materials and methods. Confirming reports on
osteoblast cells, CD54, Nuclear factor of kappa light poly-
peptide gene enhancer in B-cells 2 (NFKB2), Fas (CD95),
transforming growth factor beta (TGF-b), vascular endothe-
lial growth factor (VEGF)-A, endothelial (EDN)1, interleukin
(IL)-6, IL-8, and monocyte chemotactic protein (MCP)-1 were
found to be constitutively expressed. Cytokines that stimu-
late osteoclast activity such as granulocyte monocyte colony
stimulating factor, TNF-a, and IL-1 were not detected like
HLA-DR, CD80, CD86, IFN-g, FasL (CD95L), IL-2, IL-4, IL-
10, and IL-18 messenger RNAs (mRNAs). Confirming the
observations made using flow cytometry, rhIFN-g strongly
increased the expression of HLA-DR and CD54 genes in fetal
bone cells. Relative quantities (RQs) were 10,495$ 6,309
( p< 0.01) and 17.0$ 12.6 ( p< 0.05), respectively. This cy-
tokine had no effect on CD80 or CD86. Treatment with
rhTNF-a upregulated CD54 expression (RQ 8.0$ 1.6,
p< 0.001), but had no effect on HLA-DR, CD80, or CD86.
Table 3. Immune Profile of Fetal Bone Cells (Selection of Genes)
Inducible with:
Refseq Number Gene name Function IFN-g TNF-a
Genes Constitutively Expressed
NM_002982 CCL2 Chemokine C-C ligand 2 (MCP-1) þ
NM_001397 ECE1 Endothelin converting enzyme 1
NM_000201 ICAM1 Intercellular adhesion molecule 1
(CD54), human rhinovirus receptor
þþ þ
AF080158 IKBKB Inhibitor of kappa light polypeptide
gene enhancer in B-cells, protein kinase beta
NM_000600 IL6 Interleukin 6 (interferon, beta 2)
NM_000584 IL8 Interleukin 8 þþ
NM_002502 NFKB2 Nuclear factor of kappa light polypetide
enhancer in B-cells 2 (p49=p100)
þ
NM_000660 TGFB1 Transforming growth factor b1
NM_000043 TNFRSF6 Tumor necrosis factor receptor superfamily,
member 6 (Fas, CD95)
þ
NM_003376 VEGFA Vascular endothelial growth factor A
NM_001955 EDN1 Endothelin
Genes Not Constitutively Expressed
NM_005191 CD80 CD80 antigen (CD28 antigen ligand 1,
B7-1 antigen)
NM_006889 CD86 CD86 antigen (CD28 antigen ligand 2,
B7-2 antigen)
NM_000758 CSF2 Colony stimulating factor 2
(granulocyte-macrophage)
NM_019111 HLA-DRA Major histocompatibility complex,
class II, DR alpha
þþþ
NM_002124 HLA-DRB1 Major histocompatibility complex,
class II, DR beta 1
NM_012092 ICOS Inducible T-cell co-stimulator
NM_000619 IFNG Interferon gamma
NM_000572 IL10 Interleukin 10
NM_001562 IL18 Interleukin 18
(interferon-gamma-inducing factor)
NM_000575 IL1A Interleukin 1 alpha þ
NM_000576 IL1B Interleukin 1 beta þ
NM_000586 IL2 Interleukin 2
NM_000589 IL4 Interleukin 4
NM_000625 NOS2A Nitric oxide synthase 2A þþþ
NM_000594 TNF Tumor necrosis factor superfamily, member 2
NM_000639 TNFSF6 Tumor necrosis factor (ligand)
superfamily, member 6 (FasL, CD95L)
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rhTNF-a upregulated NFKB2 (p100) (RQ 2.5$ 0.5,
p< 0.001). Differentiation did not change the gene expres-
sions of HLA-DR, CD54, CD80, or CD86 on fetal bone cells
(data not shown).
In vitro immunomodulatory properties of bone cells
on previously stimulated and actively proliferating PBMCs
The in vitro antiproliferative effect of fetal and adult bone
cells and adult BM-MSCs from five different donors each
was tested on proliferating PBMCs stimulated with anti-
CD3e CD28mAbs as described in the Methods section. All
cells were at the same culture passage (third). In two of the
five fetal cell samples, the PBMC proliferation was fetal cell–
number dependent, with a significant reduction (56%) at
10,000 cells (1:10 fetal cell–to-PBMC ratio). Further reduction
(87%) of PBMC proliferation was observed with 50,000
fetal cells (1:2 fetal cell–to-PBMC ratio) (Fig. 1 A, dark bars).
However, the remaining three fetal cell samples showed a
different pattern of PBMC proliferation reduction; this was
significant (68%) only with the highest fetal cell concentra-
tion (1:2 fetal cell–to-PBMC ratio) while remaining basically
ineffective up to and including the 1:10 fetal cell–to-PBMC
ratio (Fig. 1A, white bars). This pattern was not observed in
any of the BM-MSCs or adult bone cells (Fig. 1B, C), which
displayed an antiproliferative effect similar to each other’s
and to those of the two fetal cells above.
An identical pattern of impaired antiproliferative effect
was also observed with one sample of fetal skin cells (data
not shown). The significance of this finding is under inves-
tigation, because there is no obvious stringent association
with other cell characteristics. The antiproliferative property
of the adult MSCs tested was independent of whether they
were irradiated, and the PBMCs were not stimulated by
stromal cells alone (data not shown).
Discussion
In this study, fetal bone cells were characterized and
compared with adult BM-MSCs and adult bone cells for
in vitro immunological properties. First, we demonstrated
that fetal and adult bone cells share similar expression pat-
terns for markers known to be involved in bone metabolism,
such as Stro-1, ALP, CD10, the adhesion molecules CD44 and
CD54, and b2-microglobulin. Stro-1þ =ALPþ bone marrow
cells were found to represent a preosteoblastic stage of de-
velopment, whereas Stro-1–=ALPþ and Stro-1–=ALP– cells
appeared to represent fully differentiated osteoblasts.27 We
observed that fetal bone cells and BM-MSCs are Stro-
1þ =ALPþ , whereas ALPþ adult bone cells showed an
intermediate pattern concerning Stro-1, indicating a more-
differentiated osteoblastic phenotype.
The presence of CD10 assessed on fetal and adult bone
cells in this study was previously described on osteoblasts;
its endopeptidase function could be involved in the process
of bone formation.28
A strong and constitutive expression of CD10 and CD44
was described on cultured human osteoblasts in flow
cytometry studies29–31 and on human bone tissue sections
using immunohistochemistry.32 Other authors described ex-
pression of CD44 antigen, a multifunctional adhesion mole-
cule that binds to extracellular matrix molecules such as
hyaluronate,33 type I collagen, and fibronectin34 during the
change from osteoblast to osteocyte.35 However, the pres-
ence of CD44 in osteoblastic cells at various maturational
stages was assessed in rat fetal bone at the mRNA and
protein levels.36
The presence of CD54 on osteoblasts is well docu-
mented,30,37 and its upregulation on osteoblastic cells con-
secutive to CD44 stimulation by fragmented hyaluronan was
shown to facilitate osteoclastogenesis.38,39 In accordance with
our findings, TNF-a and IFN-g signal transduction pathways
activate CD54.40 These cytokines act via nuclear factor kappa
beta or signal transducers and activators of transcrip-
tion proteins (STAT), respectively, and synergistically when
0
20
40
60
80
100
120
140
400 2000 10000 50000
cell number
PB
M
C 
re
si
du
al
 
pr
ol
ife
ra
tio
n 
(%
)
A
0
20
40
60
80
100
120
140
400 2000 10000 50000
cell number
PB
M
C 
re
si
du
al
 
pr
ol
ife
ra
tio
n 
(%
)
B
0
20
40
60
80
100
120
140
400 2000 10000 50000
cell number
PB
M
C 
re
si
du
al
 
pr
ol
ife
ra
tio
n 
(%
)
C
FIG. 1. Residual proliferation of anti-CD3a=CD28mAbs
antibody-stimulated peripheral blood mononuclear cells
(PBMCs) in the presence of increasing numbers of irradiated
fetal bone cells (A), adult bone marrow mesenchymal cells
(BM-MSCs) (B), and adult bone cells (C). The proliferation of
100,000 stimulated PBMCs was measured according to 3H-
thymidine uptake. Such proliferation in the presence of in-
creasing numbers of each type of cell (residual proliferation)
was normalized to that of the stimulated PBMCs alone. Each
bar (y-axis) represents the percentage of residual prolifera-
tion of the PBMCs at each concentration (50,000 to 400) of the
co-cultured cells. All primary cell cultures, five samples for
each type, had been expanded for three passages. In panel A,
the white bar represents the PBMC residual proliferation of
three different fetal primary cultures displaying a similar
pattern; the black bar is related to the remaining two.
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present together. Two regions of the CD54 promoter medi-
ating the cytokine responses were reported, and they were
found to be necessary for synergism; thus, both transcription
factor complexes function independently to increase the
transcription initiation.41 TNF-a induces NFKB2 (p100) ex-
pression at the mRNA and protein levels in human mono-
cytes, whereas IFN-g does not have such an effect. An
increase in the transcription rate and mRNA stability was
shown to mediate the observed induction of expression.42
We report in this study an induction of NFKB2 (p100) gene
expression when fetal bone cells are in the presence of rTNF-
a but not with rIFN-g. This could explain the strong upre-
gulation of CD54 observed. The synergistic effect of rTNF-a
and rIFN-g on CD54 was observed for fetal bone cells, adult
MSCs and adult osteoblasts.
In addition to its cell surface expression where b2-
microglobulin is non-covalently associated with the heavy
chain of HLA-I antigens,43 the production of b2-microglobulin
by human osteoblasts and its possible role as a local regulator
of bone metabolism were described.44,45 Controversy still sur-
rounds the exact role of b2-microglobulin in normal and
abnormal bone physiology due to the absence of an identified
receptor and the disagreement concerning its mitogenic
effect.46
According to the results presented here, MSCs were re-
cently described to express CD44 and HLA-I but not CD80,
CD86, or HLA-II,47 whereas adult osteoblasts were shown to
express CD54, CD80, CD86, and HLA-DR.29
Second, we investigated the interaction between fetal os-
teoblasts and lymphocytes. We report that fetal bone cells
inhibited in vitro the proliferation of stimulated PBMCs, al-
though with patterns not always comparable with those of
adult mesenchymal and bone cells. The antiproliferative
property observed on anti-CD3e- and anti-CD28-stimulated
PBMCs did not depend on the active proliferation of fetal
cells.
Non-induced fetal bone cells showed low and no expres-
sion of HLA-I and HLA-II, respectively. Moreover, the
costimulatory molecules CD80 and CD86 displayed on cells
involved in antigen presentation and T cell activation were
poorly expressed on fetal bone cells. Fetal MSCs isolated
from fetal liver at a median gestational age of 9 weeks (range
6–10 weeks) were shown to express a moderate level of
HLA-I, whereas HLA-II was uniformly negative.48 Recently,
bone marrow fetal MSCs isolated from older fetuses (23–24
weeks) were described to be HLA-I positive in more than
50% of the cells tested and HLA-II negative (<10%).49 These
observations, taken together with ours, point out the im-
portance of the organ and the gestational age. Donor varia-
tion could also not be excluded. For this study, fetuses of 13,
14, 15, and 16 weeks’ gestational age were used. HLA-I an-
tigens appear early in embryonic development, and HLA-II
markers appear later, usually between the 20th and the 32nd
weeks of gestation for humans.50
In mice, class I gene expression is detectable at the mid-
somite (10-day) stage but can be induced earlier by inter-
ferons, suggesting that interferon is the physiologic inducer
of MHC expression.51 We observed the induction of HLA-I
by rINF-g and rTNF-a on fetal cells, MSCs, and adult bone
cells, as previously demonstrated for MSCs isolated from
bone marrow aspirates,52 whereas HLA-II was only upre-
gulated by rINF-g. This last observation was associated with
a strong upregulation of HLA-DR gene expression, which is
in accordance with previous studies on adult osteoblasts,53
dermal fibroblasts,54 synovial fibroblasts,55 and chon-
drocytes.56 Cytokine treatments did not affect costimulatory
molecules CD80 and CD86, as already demonstrated for
IFN-g on osteoblasts57 and MSCs.58 However, fetal MSCs
exposed to IFN-g for 7 days, thus expressing HLA class I
and II molecules, inhibit lymphocyte like with adult MSCs.48
Hence, despite the up-regulation of HLA-II alloantigens,
other phenomena induced by IFN-g appear to amplify the
antiproliferative effect that fetal MSCs exert on lymphocyte
proliferation. Thus, MSCs do not escape alloreactivity and
suppress lymphocyte alloreactivity merely because they lack
HLA class II antigens. It has been reported that a soluble
factor could lead to suppression of mixed lymphocyte cul-
ture proliferation58 and that TGF-b and HGF secreted by
MSCs could function synergically.59 We observed strong
expression of TGF-b in fetal bone cells.
In this study, adult osteoblasts were always HLA-Iþ,
whereas HLA-II was weakly expressed (*15%). Expression
of HLA-DR has been described on osteoblasts obtained af-
ter mandibular surgery (13–54%)30 and HLA-DRþ or HLA-
DR– osteoblasts produced osteocalcin when stimulated with
1,25-di-hydroxyvitamin D3.53 It was suggested that HLA-
IIþ osteoblasts could play a role in local T lymphocyte ac-
tivation.30,57
Finally, we investigated for the first time immunological
properties of human fetal osteoblasts at the gene expression
level. We observed that TGF-b, VEGF-A, EDN1, IL-6, and
MCP-1 are constitutively expressed. TGF-b is mainly pro-
duced in bones,60,61 and fetal osteoblasts from rats and calves
can synthesize and secrete TGF-b. It could function as an
autocrine growth factor on these cells, with mitogenic
properties.62 As mentioned above, TGF-b could participate in
the antiproliferative effect observed on blood cells,59 whereas
VEGF-A and EDN1 might participate in the cross-talk be-
tween osteoblasts and endothelial cells during bone forma-
tion and remodeling. From the perspective of using fetal
bone cells for tissue engineering, this could be of particular
interest, because vascularization of the scaffold seeded with
cells will be crucial for the repair process. Bone morphoge-
netic proteins stimulate angiogenesis through the production
of VEGF-A by osteoblasts.63 Murine preosteoblasts express it
in a differentiation-dependent fashion, and exogenous
VEGF-A stimulated osteoblast differentiation,64 whereas
EDN1 promoted osteoblastic proliferation and differentia-
tion.65 The IL-6 gene expression is closely associated with the
differentiation of mesenchymal cells to osteoblasts and was
detected in sections of human developing osteophytes66 and
in human osteoblasts in vitro.67 Production of IL-6 and IL-8
but not IL-4 or TNF-a was observed in differentiated osteo-
blasts.68 MCP-1 is induced during inflammation and in de-
velopmentally regulated bone remodeling.69
We conclude that fetal bone cells share properties with
adult BM-MSCs concerning surface markers involved in
bone metabolism. Moreover, fetal bone cells and BM-MSCs
do not present HLA-II or the co-stimulatory molecule CD80,
on their cytoplasmic membrane, which play a role in im-
mune recognition, even if the former was inducible with
rIFN-g. In the perspective of their use in tissue engineering,
fetal bone cells could be selected for their osteogenic
and immune-related properties. These, along with their
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previously reported rapid growth,22 ease of cell banking, and
associated safety,70 may make them a viable alterative to
adult BM-MSCs in bone tissue engineering.
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